On December 10, 2021 Targovax ASA (the "Company") on 1 December 2021, reported the commencement of the subscription period for the rights issue (the "Rights Issue") and the receipt of subscription rights in the Rights Issue by certain primary insiders and close associates of primary insiders of the Company (Press release, Targovax, DEC 10, 2021, View Source [SID1234596736]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Diane Mellett, Board member and primary insider in Targovax, has on 9 December 2021, exercised 51,880 subscription rights in the Rights Issue, entitling Diane Mellett to be allocated 51,880 offer shares in the Rights Issue at a price per offer share of NOK 1.72, subject to the Rights Issue being completed.